# Semaglutide: Research Overview — Peptides Long Island > A literature summary of semaglutide, the FDA-approved GLP-1 receptor agonist and lead compound on this guide. Covers mechanism, landmark trial results across diabetes, weight, cardiovascular, and kidney outcomes, and safety cautions. An FDA-approved GLP-1 receptor agonist with trial data spanning diabetes, weight management, cardiovascular risk, and kidney disease — the benchmark the other compounds on this guide are measured against. ## The short version Semaglutide is a **GLP-1 receptor agonist** — a synthetic peptide that mimics glucagon-like peptide-1, a gut hormone released after eating that helps regulate blood sugar and appetite. It is the lead compound on this guide and the one with the most extensive published evidence by a wide margin: FDA approval for type 2 diabetes, chronic weight management, reducing cardiovascular events in adults with established heart disease, and — as of 2025 — a liver condition called MASH. In the STEP 1 weight trial, semaglutide produced an average -14.9% body-weight change versus -2.4% with placebo over 68 weeks [14]. In SELECT, a trial of over 17,000 adults with cardiovascular disease, it cut major cardiovascular events by 20% relative to placebo [13]. In FLOW, it reduced serious kidney-disease events by 24% in people with type 2 diabetes and chronic kidney disease [12]. Honest context: in a head-to-head trial, semaglutide was outperformed on weight loss by dual-receptor agonism, and this guide's own [retatrutide](/retatrutide) posted still-larger Phase 2 figures [11]. This page lists no dose as advice and offers no medical guidance. ## What it is Semaglutide is a 31-amino-acid synthetic analogue of human GLP-1, sharing roughly 94% of its sequence with the natural hormone. Two changes give it staying power in the body: at position 8, the amino acid alanine is swapped for a synthetic one that blocks the enzyme (DPP-4) that would otherwise quickly break the molecule down, and at position 34, lysine is replaced with arginine. A remaining lysine is then attached to a C18 fatty-acid side chain, which causes the peptide to bind strongly — but reversibly — to albumin, a protein that circulates abundantly in blood. That albumin binding shields semaglutide from being filtered out by the kidneys or broken down quickly, stretching its natural cousin's few-minutes half-life out to roughly a week and making once-weekly dosing possible. Semaglutide is approved in both an injectable and an oral tablet form. ## How it works Semaglutide activates GLP-1 receptors throughout the body. In the pancreas, it boosts insulin release only when blood sugar is already elevated — a glucose-dependent action that limits the risk of blood sugar dropping too low — while suppressing the release of glucagon, a hormone that would otherwise raise blood sugar further. It also slows how quickly the stomach empties, which extends the feeling of fullness after a meal and contributes to nausea as a side effect. Its effect on body weight, though, is thought to be mostly a brain effect rather than a purely metabolic one. Semaglutide reaches appetite-control circuits in the hypothalamus and brainstem, activating neurons that signal fullness and suppressing ones that drive hunger, which reduces both total food intake and the background mental preoccupation with food that many describe as 'food noise.' A rodent mechanistic study confirmed this central action directly, showing reduced food intake and altered food preference with no accompanying drop in energy expenditure [16]. Beyond glucose and weight, GLP-1 receptors in the heart and kidneys appear to mediate separate protective effects now confirmed in large outcome trials [12][13]. ## What the research shows *Head-to-head against a dual agonist.* In a 72-week trial of 751 adults with obesity, semaglutide at its maximum tolerated dose produced -13.7% mean weight loss, compared with -20.2% for a dual GIP/GLP-1 agonist tested against it (P<0.001) — a roughly 6.5-percentage-point gap that places semaglutide as the benchmark newer, multi-receptor compounds are compared against, including this guide's own retatrutide [11]. *Weight management (STEP 1).* In 1,961 adults with overweight or obesity and no diabetes, once-weekly semaglutide produced -14.9% mean body weight at 68 weeks versus -2.4% with placebo — a treatment difference of roughly 12.4 percentage points [14]. *Cardiovascular outcomes (SELECT).* In 17,604 adults with established cardiovascular disease and overweight or obesity but no diabetes, semaglutide reduced the combined rate of cardiovascular death, non-fatal heart attack, or non-fatal stroke versus placebo (hazard ratio 0.80), a 20% relative risk reduction [13]. *Kidney outcomes (FLOW).* In 3,533 adults with type 2 diabetes and chronic kidney disease, semaglutide reduced a composite of kidney failure, major eGFR decline, or kidney/cardiovascular death versus placebo (hazard ratio 0.76), a 24% lower risk [12]. *Cardiovascular outcomes in diabetes (SUSTAIN-6).* In 3,297 adults with type 2 diabetes at high cardiovascular risk, semaglutide reduced the same three-part cardiovascular composite (hazard ratio 0.74), though rates of diabetic-retinopathy complications were higher in the semaglutide group (hazard ratio 1.76) [17]. *Safety profile.* A dedicated safety review characterizes semaglutide's overall risk-benefit balance as favorable in type 2 diabetes, with mostly mild-to-moderate gastrointestinal effects (nausea in roughly a third of patients), an increased risk of gallbladder disease, and pancreatic- and thyroid-cancer signals that remain unconfirmed given their low incidence [15]. ## Reported effects, cautions & safety People describing their experience with semaglutide in patient communities report a consistent cluster of effects, compiled here from published patient-experience data. **These reports are anecdotal, not clinical evidence** and never include a specific dose. The most frequently described benefit is a marked quieting of food-related thoughts — many say sugar and fried-food cravings drop sharply and portions shrink naturally. Weight loss follows steadily over months, and people using it for type 2 diabetes commonly describe improved blood-sugar readings. A recurring, unexpected theme in community discussion is a reduced interest in alcohol. On the adverse side, nausea is the dominant complaint, typically peaking during dose increases and easing over the following weeks; sulfur-smelling burps, alternating constipation and diarrhea, acid reflux, and early fatigue on injection day are all frequently mentioned. A smaller group reports hair shedding and a more hollow or gaunt facial appearance after months of rapid weight loss — both widely attributed to the pace of weight loss itself rather than to the drug directly. Cited cautions from the clinical literature: - **Gastrointestinal intolerance during dose escalation** is the leading clinical adverse effect and the main driver of discontinuation [15]. - **Medullary thyroid carcinoma / MEN-2 (boxed warning):** based on rodent tumor data; a personal or family history of either is a contraindication, though the human signal remains unconfirmed [15]. - **Acute pancreatitis** is a class warning, though quantifying the risk precisely is limited by low incidence [15]. - **Gallbladder and biliary disease** risk is increased, attributed largely to the rate of weight loss itself [15]. - **Diabetic retinopathy complications** were significantly more frequent in patients with pre-existing retinopathy undergoing rapid blood-sugar correction [15][17]. - **Weight regain after stopping:** extension data from the pivotal weight-management trial show participants regained a meaningful share of lost weight within a year of discontinuation, framing this as chronic rather than curative therapy [14]. - **A portion of weight lost is lean muscle mass** rather than fat, a body-composition pattern documented across the same trial program [14]. ## Where it fits in Metabolic & Weight Research Semaglutide is the benchmark on this guide — the compound that proved a single-receptor incretin mimetic could deliver large, durable weight loss alongside cardiovascular and kidney benefit at population scale. [Retatrutide](/retatrutide) extends that story mechanistically by adding a glucagon receptor arm and posted larger Phase 2 numbers, though without semaglutide's regulatory standing or trial maturity [9][11]. [MOTS-c](/mots-c) works through an entirely different route and has essentially no human trial data by comparison. Reading semaglutide alongside the other two clarifies just how much evidentiary ground separates an approved medicine from an investigational compound and a research-only peptide. See the [comparison page](/compare) for the side-by-side. ![Semaglutide research illustration — abstract incretin pathway motifs in cobalt](/images/semaglutide.webp) --- Peptides Long Island pairs every research finding with its citation and its caveat — a field guide to metabolic peptides, not a clinic or a store.